MedPath

Clinical Trial to Evaluate the Effect of an Extract of Sclerocaya Birrea on Prediabetic Subjects

Not Applicable
Completed
Conditions
PreDiabetes
Interventions
Dietary Supplement: Placebo
Registration Number
NCT04132908
Lead Sponsor
Universidad Católica San Antonio de Murcia
Brief Summary

It consists in the intake, during a period of 10 weeks, of a nutraceutical (natural extract of Sclerocarya birrea). It is a clinical trial, during which certain parameters of the glucidic metabolism will be measured analytically. Other secondary variables such as lipid profile, inflammatory markers, blood pressure, endothelial function and body composition will also be determined.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Age: 18-65 years.

  • Diagnosis of prediabetes according to the American Diabetes Association.

    • Altered fasting glucose (95-125 mg / dl).
    • Glucose intolerance (oral glucose tolerance test with glycemia at 2 hours between 140 - 199 mg / dl).
    • Hemoglobin glycated between 5.7 and 6.4%.
  • Subjects with body mass index between 18-35 Kg / m2.

  • Stable food habits: there is no gain or weight loss of more than 5 kg in the ten weeks.

  • I do not consume foods rich in Screrocaria Birrea.

Exclusion Criteria
  • Subjects with a history of any type of liver or kidney pathology.
  • Use of medications that may interfere with glucose metabolism.
  • Consumption of alcohol greater than 20 g / day.
  • History of allergic hypersensitivity or poor tolerance to any component of the products under study.
  • Participation in another clinical trial in the three months prior to the study
  • Lack of will or inability to comply with clinical trial procedures.
  • Pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
endothelial functionThe measurements of endothelial function are taken with an ultrasound on two different occasions. The measurements will be made at baseline and after ten weeks of product consumption. Up to 10 weeks

Changes in the dilatation of the Humeral artery.

blood samplesIt is performed in the laboratory with the ILAB 600 analyzer. Blood samples are analyzed on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product. Up to 10 weeks

Changes in lipidic profile:( total cholesterol, HDL and LDL) , it will be measured in mg/dl.

nutritional recordThe dietary intake will be controlled by a diary in which meals will be recorded for three days and on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product. Up to 10 weeks

Potential changes in the dietary survey were controlled with a food diary

body compositionBody measurements are taken with a Tanita on two different occasions. The measurements are made at the beginning and after eight weeks of consumption of the product. Up to 10 weeks

Changes in body composition were measured with a TANITA

Physical activity testQuality of life measurements are taken with physical activity test on two different occasions. The measurements are made at the beginning and after ten weeks of consumption of the product. Up to 10 weeks

Change in physical activity with the World Physical Activity Questionnaire (GPAQ)

glucose tolerance testThe glucose measurements in venous blood are taken with a glucometer on three different occasions (1: at baseline before consumption of the product, 2: at five weeks and 3: ten weeks after ingestion of the layer product observe the changes) .

Venous blood samples are taken from the finger at different times.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Catholic University of Murcia

🇪🇸

Murcia, Spain

© Copyright 2025. All Rights Reserved by MedPath